Therachon lands $5 mln Series A
Basel, Switzerland-based Therachon AG, a biotech company focused on rare genetic diseases, has secured an additional $5 million in Series A funding. Therachon's investors include Versant Ventures, Inserm Transfer Initiative OrbiMed and Bpifrance. In addition to the funding, Therachon has named Dr. Luca Santarelli as CEO and added Bpifrance’s Chahra Louafi to its board of directors.
6 January 2017•1 min read
